Phaseline

Targets › CLU

CLU (Clusterin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology.

[Isoform 1]: Functions as extracellular chaperone that prevents aggregation of non native proteins. Prevents stress-induced aggregation of blood plasma proteins. (UniProt, P10909)

Open in Phaseline: the race on CLU, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Alethia BiotherapeuticsSotevtamab
Anti-tumor-associated secreted clusterin (TA-sCLU) monoclonal antibody
CLUPhase 2Metastatic Colorectal Cancer–

Conditions

Metastatic Colorectal Cancer (1)

Modalities

antibody (1)

Companies

Alethia Biotherapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.